Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAZERATI: Mechanistic Studies of Biologics in Rheumatoid Arthritis
NCT02353780Phase 4Terminated
- Sponsor
- Dr. Larry W. Moreland
- Start
- Mar 2015
- Primary completion
- Dec 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of abatacept and tocilizumab in rheumatoid arthritis (RA) (3 arms), sponsored by Dr. Larry W. Moreland. Primary endpoint: Changes in Frequencies of Peripheral Blood Immune Cell Subsets at 3 months. Started Mar 2015; status: terminated.
02
Drugs
abatacepttocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02353780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353780.